/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Hyperion DeFI Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.75 -0.0437(-4.37%) HYPD at 09 Dec 2025 05:46 PM Biotechnology
Lowest Today 3.705
Highest Today 3.86
Today’s Open 3.835
Prev. Close 3.89
52 Week High 17.18
52 Week Low 0.85
Day’s Range: Low 3.705 High 3.86
52-Week Range: Low 0.85 High 17.18
1 day return -
1 Week return -3.84
1 month return -36.11
3 month return -57.14
6 month return -66.03
1 year return -
3 year return -
5 year return -
10 year return -

Institutional Holdings

Market Status

Fundamentals

Market Cap 57.45 M

PB Ratio 1.7016

PE Ratio 0.0

Enterprise Value 64.50 M

Total Assets 3.67 M

Volume 177603

Company Financials

Fund house & investment objective

Company Information Hyperion DeFi, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025. Hyperion DeFi, Inc. was founded in 2014 and is based in New York, New York.

Organisation Biotechnology

Employees 13

Industry Biotechnology

CEO Mr. Hyunsu Jung

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow